Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's ...

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of Parkinsonism risk, per Yi Lin, MD, PhD.

Panelists discuss strategies for medication adherence and patient education, emphasizing the importance of proactive communication and support from the entire health care team.

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Patients with stage III and high-risk stage II colon cancer who participated in an exercise program saw improved disease-free ...

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with ...

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform ...